Loading quotes...

Forecast

The analysts' average price target is €12.72 (+73.30%). The median is €13.62 (+85.56%).

Buy
  5
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Kamada achieves record revenue in first half — revenue +13% to $100.2m

    Kamada reported a 13% revenue increase in H1 2026 to $100.2m and a Q2 revenue jump of 23% to $54.9m. Net income rose to $13.4m ($0.23 per share) and adjusted EBITDA climbed to $25.7m (margin 26%). The company signed a three‑year distribution agreement worth about $50m and reaffirmed its 2026 guidance of $200–205m in revenue and $50–53m in adjusted EBITDA. » More on de.investing.com


  • Kamada schedules annual general meeting for 5 August 2026 in Rehovot

    Kamada has set the annual general meeting of shareholders for Wednesday, 5 August 2026, at 16:00 Israeli time at its offices at Holzman Street 2, Weizmann Science Park, Rehovot. The notice of meeting, proxy statement and voting card have been prepared and accompany the mandatory announcement. No further details were published regarding the agenda or proposed resolutions. » More on de.investing.com


  • Kamada receives FDA approval for plasma center in San Antonio

    Kamada has received FDA approval for its new plasma donation center in San Antonio and can sell commercial normal source plasma there. The 11,100 sq ft facility with up to 50 donor beds has a planned annual capacity of around 50,000 liters and is expected, at full capacity, to generate $8–10 million in annual revenue from normal source plasma. The center is also intended for specialty plasma; with it Kamada will operate three FDA-approved centers in Texas and is seeking an EMA inspection. The company has a strong balance sheet with a current ratio of 4.07; analysts see the stock as potentially undervalued at $8.20 with price targets of $11–15. » More on de.investing.com


  • Kamada misses Q4 forecasts; stock slips in premarket

    Kamada reported Q4 2025 EPS of $0.06 (expected $0.10) and revenue of $44.68m (expected $45.42m), prompting the stock to fall about 3% in premarket trading. For the full year, revenue rose 12% to $180.5m and net profit increased 40%. The company lowered its gross margin by 100 basis points, announced a dividend of $0.25 and issued EPS guidance of $0.11 for Q2 2026 and $0.13 for Q3 and Q4 2026. » More on de.investing.com


  • Kamada announces first-ever cash dividend of $0.25 per share

    Kamada declared a cash dividend of $0.25 per share, totaling about $14.4 million; payment will be made on April 6, 2026 to shareholders of record at the close of trading on March 23, 2026. The board adopted an annual cash dividend policy to distribute at least 50% of annual net income, subject to management discretion and legal requirements. The company cites strong 2025 financial results, a high liquidity ratio (current ratio 4.03) and a market capitalization of $511 million as the basis for the decision. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Kamada has already paid €0.36 in dividends. The last payout was in September.

Financials

In the last quarter, Kamada had revenue of €45.09M and net profit of €6.92M
(EUR) September 2026
YoY
Revenue 45.09M 12.55%
Gross profit 20.22M 20.07%
Net profit 6.92M 53.41%
EBITDA 12.4M 40.66%

Fundamentals

Metric Value
Market capitalization
€423.85M
Number of shares
57.68M
52-week high/low
€8.49 - €5.99
Dividend yield
2.02%
Dividends TTM
€0.15
Next dividend
€0.13
Beta
0.13
P/E ratio
18.68
PEG ratio
0.96
P/B ratio
1.74
P/S ratio
2.38

Company profile

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Name
Kamada
CEO
Amir London
Headquarters Rehovot, hm
Israel
Website
Sector
Materials
Industry
Chemicals
IPO
05/31/2013
Employees 462

Ticker symbols

Exchange Symbol
Tlv
KMDA.TA
NASDAQ
KMDA
🍪

Parqet  uses cookies. Learn more